{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:12:13Z","timestamp":1791850333295,"version":"4.3.4"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,3]],"date-time":"2014-12-03T00:00:00Z","timestamp":1417564800000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.dld.2014.09.025","type":"journal-article","created":{"date-parts":[[2014,11,10]],"date-time":"2014-11-10T04:45:56Z","timestamp":1415594756000},"page":"S186-S196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"S5","title":["The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C"],"prefix":"10.1016","volume":"46","author":[{"given":"Zobair","family":"Younossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2014.09.025_bib0005","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/apt.12625","article-title":"The impact of hepatitis C burden: an evidence-based approach","volume":"39","author":"Younossi","year":"2014","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.dld.2014.09.025_bib0010","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jhep.2013.11.009","article-title":"Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients","volume":"60","author":"Younossi","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0015","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.025_bib0020","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1473-3099(13)70074-4","article-title":"Sofosbuvir: the final nail in the coffin for hepatitis C?","volume":"13","author":"Manns","year":"2013","journal-title":"Lancet Infectious Diseases"},{"key":"10.1016\/j.dld.2014.09.025_bib0025","series-title":"VA, California Panels Urge Costly Hepatitis C Drugs For Sickest Patients","author":"Appleby","year":"2014"},{"key":"10.1016\/j.dld.2014.09.025_bib0030","series-title":"Patient-reported outcome measures: use in medical product development to support labeling claims","author":"FDA Guidance for Industry","year":"2009"},{"key":"10.1016\/j.dld.2014.09.025_bib0035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11136-006-9131-y","article-title":"Generic and disease-specific health related quality of life of liver patients with various aetiologies: a survey","volume":"16","author":"van der Plas","year":"2007","journal-title":"Quality of Life Research"},{"key":"10.1016\/j.dld.2014.09.025_bib0040","unstructured":"The Health Measurement Research Group. Health related quality of life tools. Obtained from the world wide web at: http:\/\/www.healthmeasurement.org\/Measures.html [accessed 16.04.14]."},{"key":"10.1016\/j.dld.2014.09.025_bib0045","unstructured":"Quality Metrics Hepatitis Quality of Life Questionnaire (HQLQv2). Obtained from the world wide web at: http:\/\/www.qualitymetric.com\/WhatWeDo\/DiseasespecificHealthSurveys\/HepatitisQualityofLifeQuestionnaireHQLQv2\/tabid\/193\/Default.aspx [accessed 15.04.14]."},{"key":"10.1016\/j.dld.2014.09.025_bib0050","unstructured":"Centers for Disease Control \u2013 Health Related Quality of Life. Obtained from the world wide web at: http:\/\/www.cdc.gov\/HRQoL\/concept.htm [accessed 15.04.14]."},{"key":"10.1016\/j.dld.2014.09.025_bib0055","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1440-1746.2006.04456.x","article-title":"Health-related quality of life of chronic liver disease patients with and without hepatocellular carcinoma","volume":"22","author":"Kondo","year":"2007","journal-title":"Journal of Gastroenterology & Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0060","doi-asserted-by":"crossref","first-page":"7786","DOI":"10.3748\/wjg.v12.i48.7786","article-title":"Factors influencing health-related quality of life in chronic liver disease","volume":"12","author":"Sobhonslidsuk","year":"2006","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2014.09.025_bib0065","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1111\/j.1365-2036.2006.02934.x","article-title":"Determinants of quality of life in chronic liver patients","volume":"23","author":"Gutteling","year":"2006","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2014.09.025_bib0070","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gut.45.2.295","article-title":"Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease","volume":"45","author":"Younossi","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.dld.2014.09.025_bib0075","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2036.2009.04061.x","article-title":"Predictors of health-related quality of life in patients with chronic liver disease","volume":"30","author":"Afendy","year":"2009","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2014.09.025_bib0080","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jhep.2012.07.020","article-title":"Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema","volume":"57","author":"Sol\u00e0","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0085","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MEG.0b013e3283319975","article-title":"Quality of life in cirrhosis is related to potentially treatable factors","volume":"22","author":"Les","year":"2010","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0090","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1023\/B:QURE.0000040797.17449.c0","article-title":"The Liver Disease Symptom Index 2.0: validation of a disease-specific questionnaire","volume":"13","author":"van der Plas","year":"2004","journal-title":"Quality of Life Research"},{"key":"10.1016\/j.dld.2014.09.025_bib0095","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0895-4356(94)90162-7","article-title":"The development of a short generic version of the sickness impact profile","volume":"47","author":"De Bruin","year":"1994","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1016\/j.dld.2014.09.025_bib0100","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1524-4733.2009.00585.x","article-title":"A methodology for successfully producing global translations of patient reported outcome measures for use in multiple countries","volume":"13","author":"Two","year":"2010","journal-title":"Value in Health"},{"key":"10.1016\/j.dld.2014.09.025_bib0105","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1023\/A:1012588218728","article-title":"Interpreting SF-36 summary health measures: a response","volume":"10","author":"Ware","year":"2001","journal-title":"Quality of Life Research"},{"key":"10.1016\/j.dld.2014.09.025_bib0110","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.dld.2005.04.022","article-title":"Health-related quality of life (HRQOL) in chronic liver disease","volume":"37","author":"Martin","year":"2005","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2014.09.025_bib0115","first-page":"604","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Validation of version 4 of the core questionnaire","volume":"8","author":"Webster","year":"1999","journal-title":"Quality of Life Research"},{"key":"10.1016\/j.dld.2014.09.025_bib0120","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.dld.2014.09.025_bib0125","unstructured":"Tolley K. What are health utilities? Health Economics 2009. Downloaded from the world wide web at: http:\/\/www.medicine.ox.ac.uk\/bandolier\/painres\/download\/whatis\/Health-util.pdf [accessed 26.07.14]."},{"key":"10.1016\/j.dld.2014.09.025_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-1-54","article-title":"The Health Utilities Index (HUI\u00ae): concepts, measurement properties and applications","volume":"1","author":"Horsman","year":"2003","journal-title":"Health and Quality of Life Outcomes"},{"key":"10.1016\/j.dld.2014.09.025_bib0135","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1440-1746.2011.06813.x","article-title":"Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection","volume":"27","author":"Hsu","year":"2012","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0140","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1007\/s10620-006-9708-x","article-title":"Fatigue and health-related quality of life (HRQOL) in chronic hepatitis C virus infection","volume":"52","author":"Kallman","year":"2007","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/j.dld.2014.09.025_bib0145","doi-asserted-by":"crossref","first-page":"953","DOI":"10.7326\/0003-4819-121-12-199412150-00009","article-title":"The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group","volume":"121","author":"Fukuda","year":"1994","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.dld.2014.09.025_bib0150","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1001\/archinte.1995.00430190101014","article-title":"Outcome and prognosis of patients with chronic fatigue vs chronic fatigue syndrome","volume":"155","author":"Bombardier","year":"1995","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.dld.2014.09.025_bib0155","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/hep.24131","article-title":"Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States","volume":"53","author":"Stepanova","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0160","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/hep.21565","article-title":"The effects of HCV infection and management on health-related quality of life","volume":"45","author":"Younossi","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0165","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0168-8278(00)00026-X","article-title":"The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity","volume":"34","author":"McHutchison","year":"2001","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0170","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.20659","article-title":"Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment","volume":"41","author":"Spiegel","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0175","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/lt.21376","article-title":"Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index","volume":"14","author":"Dan","year":"2008","journal-title":"Liver Transplantation"},{"key":"10.1016\/j.dld.2014.09.025_bib0180","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jhep.2006.10.009","article-title":"Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis","volume":"46","author":"Bonkovsky","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0185","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/ajg.2009.346","article-title":"Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C","volume":"104","author":"John-Baptiste","year":"2009","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2014.09.025_bib0190","article-title":"Patients\u2019 preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens","author":"Stepanova","year":"2014","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.dld.2014.09.025_bib0195","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jhep.2014.04.003","article-title":"Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study","volume":"61","author":"Younossi","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0205","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.025_bib0210","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.025_bib0215","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.025_bib0220","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.025_bib0225","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.025_bib0230","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1002\/hep.27161","article-title":"Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens","volume":"59","author":"Younossi","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0235","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2013.12.006","article-title":"Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C)","volume":"60","author":"Younossi","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0240","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.cgh.2013.11.032","article-title":"Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C","volume":"12","author":"Younossi","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0245","series-title":"EASL abstract","article-title":"Ledipasvir and sofosbuvir combination improves patient-reported outcomes during treatment of chronic hepatitis c patients: results from the ION-1 clinical trial","author":"Younossi","year":"2014"},{"key":"10.1016\/j.dld.2014.09.025_bib0250","series-title":"DDW abstract","article-title":"Substantial improvement of health-related quality of life and patient-reported outcomes in chronic hepatitis C (CH-C) patients treated with ledipasvir (LDV) and sofosbuvir (SOF): results from ION-1 and 2","author":"Younossi","year":"2014"},{"key":"10.1016\/j.dld.2014.09.025_bib0255","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jval.2011.11.032","article-title":"A review of patient-reported outcome labels in the United States: 2006 to 2010","volume":"15","author":"Gnanasakthy","year":"2012","journal-title":"Value in Health"},{"key":"10.1016\/j.dld.2014.09.025_bib0260","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1177\/1039856212460597","article-title":"Anxiety and depression in Australian chronic hepatitis C outpatients: prevalence and predictors","volume":"20","author":"Stewart","year":"2012","journal-title":"Australas Psychiatry"},{"key":"10.1016\/j.dld.2014.09.025_bib0265","article-title":"Antidepressant pretreatment for the prevention of interferon alfa-associated depression: a systematic review and meta-analysis","author":"Sarkar","year":"2013","journal-title":"Psychosomatics"},{"key":"10.1016\/j.dld.2014.09.025_bib0270","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2893.2007.00956.x","article-title":"A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment","volume":"15","author":"Younossi","year":"2008","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.dld.2014.09.025_bib0275","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.025_bib0280","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.025_bib0285","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.025_bib0290","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.025_bib0295","unstructured":"Neuman T, Hoadley J, Cubanski J. The cost of a cure: Medicare's role in treating hepatitis C. Obtained from the world wide web at: http:\/\/healthaffairs.org\/blog\/2014\/06\/05\/the-cost-of-a-cure-medicares-role-in-treating-hepatitis-c\/ [accessed 20.07.14]."},{"key":"10.1016\/j.dld.2014.09.025_bib0300","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/apt.12485","article-title":"The impact of chronic hepatitis C on resource utilisation and in-patient mortality for Medicare beneficiaries between 2005 and 2010","volume":"38","author":"Younossi","year":"2013","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.dld.2014.09.025_bib0305","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMp1302973","article-title":"Hepatitis C in the United States","author":"Holmberg","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.025_bib0310","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep.25842","article-title":"Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection","volume":"56","author":"Gordon","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0315","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/cid\/ciu077","article-title":"Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006\u20132010","volume":"58","author":"Mahajan","year":"2014","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.dld.2014.09.025_bib0320","series-title":"Societal burden in hepatitis C patients: the COME study results. Abstract presented at AASLD 64th Annual Meeting, November 1\u20135, Washington, DC","author":"Ciampichini","year":"2013"},{"key":"10.1016\/j.dld.2014.09.025_bib0325","author":"Lachaine","year":"2013"},{"key":"10.1016\/j.dld.2014.09.025_bib0330","unstructured":"Ryan B. Pipeline Report: Hep C to meet its maker. Obtained from the world wide web at: http:\/\/www.hepmag.com\/printView.php?page=\/articles\/2014_pipeline_2502_25621.shtml&domain=www.hepmag.com [accessed 22.07.14]."},{"key":"10.1016\/j.dld.2014.09.025_bib0335","series-title":"Long-term outcomes of sofosbuvir (SOF) for the treatment of chronic hepatitis C infected (CHC) patients. Abstract presented at ISPOR 16th Annual European Congress, Dublin, Ireland; November 2\u20136","author":"Cure","year":"2013"},{"key":"10.1016\/j.dld.2014.09.025_bib0340","series-title":"A projection of the healthcare and economic burden in the UK. RAND Corporation report Hepatitis C. Prepared for the Hepatitis C Trust","author":"Patruni","year":"2013"},{"key":"10.1016\/j.dld.2014.09.025_bib0345","doi-asserted-by":"crossref","first-page":"e63959","DOI":"10.1371\/journal.pone.0063959","article-title":"Current and future disease progression of the chronic HCV population in the United States","volume":"8","author":"Zalesak","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.dld.2014.09.025_bib0350","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3111\/13696998.2011.566294","article-title":"The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities","volume":"14","author":"DiBonaventura","year":"2011","journal-title":"Journal of Medical Economics"},{"key":"10.1016\/j.dld.2014.09.025_bib0355","first-page":"657","article-title":"Absenteeism and productivity among employees being treated for hepatitis C","volume":"17","author":"Brook","year":"2011","journal-title":"American Journal of Managed Care"},{"key":"10.1016\/j.dld.2014.09.025_bib0360","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/hep.23726","article-title":"The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs","volume":"52","author":"Su","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0365","author":"Forlenza","year":"2013"},{"key":"10.1016\/j.dld.2014.09.025_bib0370","doi-asserted-by":"crossref","first-page":"531","DOI":"10.18553\/jmcp.2011.17.7.531","article-title":"All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective","volume":"17","author":"McAdam-Marx","year":"2011","journal-title":"Journal of Managed Care Pharmacy"},{"key":"10.1016\/j.dld.2014.09.025_bib0375","series-title":"Potential impact of improved treatment on disease burden of chronic hepatitis C in Australia. Abstract presented at the 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), November 1\u20135, Washington, DC","author":"Dore","year":"2013"},{"key":"10.1016\/j.dld.2014.09.025_bib0380","series-title":"The disease burden of chronic hepatitis C virus infection In England. Abstract presented at the 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), November 1\u20135, Washington, DC","author":"Rosenberg","year":"2013"},{"key":"10.1016\/j.dld.2014.09.025_bib0385","series-title":"The disease burden of chronic hepatitis C (HCV) virus infection in Switzerland. Abstract presented at the 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), November 1\u20135, Washington, DC","author":"Bruggmann","year":"2013"},{"key":"10.1016\/j.dld.2014.09.025_bib0390","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1440-1746.2008.05398.x","article-title":"Ribavirin in the treatment of chronic hepatitis C","volume":"23","author":"Martin","year":"2008","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0395","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/ajg.2009.346","article-title":"Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C","volume":"104","author":"John-Baptiste","year":"2009","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2014.09.025_bib0400","first-page":"S1-S-24","article-title":"Lifetime costs attributable to chronic hepatitis C from the French healthcare perspective","volume":"58","author":"Schwarzinger","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0405","unstructured":"Kaczmarek SJ. The impact of new hepatitis C drug therapy on individual Medicare Part D spending. Milliman client report. Obtained from the world-wide web at: http:\/\/www.natap.org\/2014\/HCV\/partdpremiumstudymilliman.pdf [accessed 10.08.14]."},{"key":"10.1016\/j.dld.2014.09.025_bib0410","doi-asserted-by":"crossref","DOI":"10.1002\/hep.27340","article-title":"Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virologic response","author":"Bichoupan","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0415","series-title":"Analysis of direct and indirect costs of HCV care with PEG-interferon triple therapy. Abstract presented at AASLD, Washington, DC","author":"Sethi","year":"2013"},{"key":"10.1016\/j.dld.2014.09.025_bib0420","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2014.09.025_bib0425","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2014.09.025_bib0430","series-title":"Cost per SVR of sofosbuvir vs simeprevir: treatment na\u00efve HIV-coinfected genotype 1. Abstract presented at EACS, Brussels, Belgium","author":"Dieterich","year":"2013"},{"key":"10.1016\/j.dld.2014.09.025_bib0435","series-title":"Sofosbuvir for the treatment of chronic hepatitis C: cost-effectiveness analysis including HIV-coinfected patients. Abstract presented at 10th HIV & hepatitis co-infection workshop June 12\u201313, Paris, France","author":"F\u00e9lix","year":"2014"},{"key":"10.1016\/j.dld.2014.09.025_bib0440","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijantimicag.2013.09.008","article-title":"Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection","volume":"43","author":"Lim","year":"2014","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.dld.2014.09.025_bib0445","doi-asserted-by":"crossref","DOI":"10.1111\/apt.12871","article-title":"Cost-effectiveness analysis of sofosbuvir plus peginterferon\/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection","author":"Saab","year":"2014","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.dld.2014.09.025_bib0450","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMc1307589","article-title":"Current and future therapies for hepatitis C virus infection","volume":"369","author":"Ghany","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.025_bib0455","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","author":"Poordad","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.025_bib0460","series-title":"Abstract AASLD","article-title":"A decision analytic model to evaluate the health outcomes of ledipasvir\/sofosbuvir (LDV\/SOF) for patients with chronic hepatitis C (HCV) genotype 1 (GT1) Infection","author":"Younossi","year":"2014"},{"key":"10.1016\/j.dld.2014.09.025_bib0465","series-title":"Recommendations for testing, managing, and treating hepatitis C","author":"American Society for the Study of Liver Disease and the Infectious Diseases Society of America","year":"2014"},{"key":"10.1016\/j.dld.2014.09.025_bib0470","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hep.27151","article-title":"Cost analysis of sofosbuvir\/ribavirin versus sofosbuvir\/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible\/intolerant individuals","volume":"60","author":"Hagan","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0475","unstructured":"AMCP Dossier Data on file, Gilead Sciences; December 2013."},{"key":"10.1016\/j.dld.2014.09.025_bib0480","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.amepre.2013.04.017","article-title":"Lifetime direct medical costs of treating type 2 diabetes and diabetic complications","volume":"45","author":"Zhuo","year":"2013","journal-title":"American Journal of Preventive Medicine"},{"key":"10.1016\/j.dld.2014.09.025_bib0485","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/QAI.0b013e3182973966","article-title":"Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care","volume":"64","author":"Farnham","year":"2013","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.dld.2014.09.025_bib0490","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/1471-2407-11-250","article-title":"Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality","volume":"11","author":"Vera-Llonch","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.dld.2014.09.025_bib0495","doi-asserted-by":"crossref","first-page":"245","DOI":"10.18553\/jmcp.2007.13.3.245","article-title":"Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data","volume":"13","author":"Bell","year":"2007","journal-title":"Journal of Managed Care Pharmacy"},{"key":"10.1016\/j.dld.2014.09.025_bib0500","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/hep.27010","article-title":"Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C","volume":"59","author":"Petta","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.025_bib0505","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2014.03.011","article-title":"Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141)","volume":"61","author":"Deuffic-Burban","year":"2014","journal-title":"Journal of Hepatology"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865814007269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865814007269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:17:57Z","timestamp":1747153077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865814007269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":100,"alternative-id":["S1590865814007269"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2014.09.025","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2014.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}